Antiangiogenic agents: current limits in thoracic oncology

作者：Dansin Eric^*; Lauridant Geraldine; Chahine Bachar

来源：Bulletin du Cancer, 2012, 99(11): 1083-1091.

DOI：10.1684/bdc.2012.1655

• antiangiogenic agent
• multi-targeted tyrosine kinase inhibitor
• bevacizumab
• lung cancer
• thoracic oncology

Antiangiogenic agents appear as major therapeutic options in renal, colorectal and breast cancer. Their part in thoracic oncology is still limited today except for bevacizumab. We review the current limits of antiangiogenic agents in terms of efficacy, activity, tolerance and therapeutic strategies. Problems about predictive biomarkers and cost-effectiveness of antiangiogenic agents in thoracic oncology are also mentioned.

• 出版日期2012-11